OncoMatch/Clinical Trials/NCT06485544
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
Is NCT06485544 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab + Etoposide + Platinum-based Therapy and Etoposide + Platinum-based Therapy for small cell lung cancer (sclc).
Treatment: Adebrelimab + Etoposide + Platinum-based Therapy · Etoposide + Platinum-based Therapy — This study is a randomized, open-label, multicenter exploratory research aiming to evaluate the efficacy and safety of Adebrelimab in combination with chemotherapy (etoposide and platinum-based therapy) as neoadjuvant treatment for resectable stage I-IIIB (stage IIIB limited to T1-4N1-2M0) small cell lung cancer (SCLC). The study is primarily conducted at Tangdu Hospital of the Fourth Military Medical University. A total of 104 patients with stage IA-IIIB SCLC (stage IIIB limited to T1-4N1-2M0) will be enrolled and randomized 1:1 to receive either Adebrelimab plus chemotherapy or chemotherapy alone. Each patient will undergo 3 cycles of study treatment followed by a 3-4 week break before surgery. Treatment will be discontinued if patients experience disease progression, intolerable drug-related adverse events, withdrawal of informed consent, or other specified conditions during the study. Effectiveness and safety outcomes will be monitored throughout the trial. The primary objective is to evaluate pathological complete response (pCR) with Adebrelimab combination therapy. Secondary objectives include assessing event-free survival (EFS), major pathological response (mPR), objective response rate (ORR), disease-free survival (DFS), and safety.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage I, II, IIIA, IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
without prior treatment with radiation
Cannot have received: chemotherapy
without prior treatment with chemotherapy
Cannot have received: targeted therapy
without prior treatment with targeted therapy
Cannot have received: surgery
without prior treatment with surgery
Cannot have received: traditional Chinese medicine
without prior treatment with traditional Chinese medicine
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L; PLT ≥ 100 × 10^9/L; Hb ≥ 90 g/L
Kidney function
Serum creatinine (sCr) ≤ 1.5 × ULN, estimated glomerular filtration rate (eGFR) ≥ 50 mL/min (Cockcroft-Gault formula)
Liver function
TBIL ≤ 1.5 × ULN; ALT, AST ≤ 2.5 × ULN (if abnormal liver function due to liver metastasis, ≤ 5 × ULN)
Cardiac function
sufficient cardiopulmonary function to tolerate planned lung resection surgery; INR ≤ 1.5 × ULN and APTT ≤ 1.5 × ULN; LVEF ≥ 50% by cardiac ultrasound
Normal organ function, as defined by the following criteria: (1) Hematological criteria ... (2) Biochemical criteria ... (3) Coagulation function ... sufficient cardiopulmonary function to tolerate planned lung resection surgery.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify